Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial

Autor: Stefan H. Hohnloser, Mick Ozkor, Gilles Montalescot, Philippe Gabriel Steg, Joerg Kreuzer, Martina Brueckmann, Takeshi Kimura, Matias Nordaby, Gregory Y.H. Lip, Jonas Oldgren, Corinna Miede, Christopher P. Cannon, Jurriën M. ten Berg, Laura Mauri, Panagiotis Vardas, Deepak L. Bhatt

Publikováno v: American Heart Journal
American Heart Journal, Elsevier, 2019, 212, pp.13-22. ⟨10.1016/j.ahj.2019.02.006⟩
Lip, G Y H, Mauri, L, Montalescot, G, Ozkor, M, Vardas, P, Steg, P G, Bhatt, D L, Hohnloser, S H, Miede, C, Nordaby, M, Brueckmann, M, Kreuzer, J, Kimura, T, Oldgren, J, Ten Berg, J M & Cannon, C P 2019, ' Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention : An ancillary analysis from the RE-DUAL PCI trial ', American Heart Journal, vol. 212, pp. 13-22 . https://doi.org/10.1016/j.ahj.2019.02.006

BACKGROUND: In the RE-DUAL PCI trial of patients with atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI), dabigatran dual therapy (110 or 150 mg bid, plus clopidogrel or ticagrelor) reduced International Society on Thromb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ab4e930b06b16ab9a51d1bf2805de93
https://doi.org/10.1016/j.ahj.2019.02.006

Are Plasma Natriuretic Peptide Levels Influenced by Automatic Pacemaker Algorithms for Ventricular Pacing Minimization?

Autor: Verena Semmler, Thomas Beier, Joerg Kreuzer M.D., Carsten Lennerz, Christof Kolb, Haitham Badran, Josef U. Dietl, Bernhard Zrenner, Alexej Strauch

Publikováno v: Pacing and Clinical Electrophysiology. 36:424-432

Background Automatic atrioventricular search hysteresis (AVSH) is designed to reduce the cumulative percentage of potentially deleterious right ventricular apical pacing (VP%) in dual-chamber pacemakers. We investigated whether minimizing VP% by AVSH

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c28684de111eea9e53ed11e8a3d8e5b9
https://doi.org/10.1111/pace.12070

Long-term Administration of 3-deazaadenosine Does Not Alter Progression of Advanced Atherosclerotic Lesions in Apolipoprotein E-deficient Mice

Autor: Hugo A. Katus, I. Pedal, Joerg Kreuzer, Berend Isermann, Florian Bea, Sara Hsin-Yi Yang, Michael R. Preusch, Erwin Blessing, Michael E. Rosenfeld

Publikováno v: Journal of Cardiovascular Pharmacology. 50:206-212

Inflammatory mechanisms are involved in initiation and progression of atherosclerotic lesions. Previous studies demonstrated antiinflammatory and consecutive antiatherosclerotic effects of the adenosine analogue 3-Deazaadenosine (c(3) Ado) on early l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f956ed2138710f1a86ccddbf52ab9915
https://doi.org/10.1097/fjc.0b013e318070c66a

Dabigatran treatment simulation in patients undergoing maintenance haemodialysis

Autor: Martina Brueckmann, Friedrich Schulze, Joerg Kreuzer, Andreas Clemens, Karl-Heinz Liesenfeld

Publikováno v: Thrombosis and haemostasis. 115(3)

SummaryPatients with atrial fibrillation requiring maintenance haemodialysis are at increased risk of ischaemic stroke and bleeds. Currently, vitamin K antagonists such as warfarin are predominantly used in these patients as limited data are availabl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50671a3351bff07bb12c6fe607b3540e
https://pubmed.ncbi.nlm.nih.gov/26467062

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

Autor: Jerrold H. Levy, Joerg Kreuzer, Pieter Willem Kamphuisen, Paul A. Reilly, Joachim Stangier, Richard A. Bernstein, Stephan Glund, Menno V. Huisman, Robert Dubiel, Jeffrey I. Weitz, Charles V. Pollack, Thorsten Steiner, John W. Eikelboom, Frank W. Sellke, Chak Wah Kam, Bushi Wang, Elaine M. Hylek

Publikováno v: Thrombosis and Haemostasis, 114(1), 198-205. GEORG THIEME VERLAG KG
Thrombosis and Haemostasis, 114(1), 198-205

SummaryIdarucizumab, a Fab fragment directed against dabigatran, produced rapid and complete reversal of the anticoagulation effect of dabigatran in animals and in healthy volunteers. The Study of the REVERS al E ffects of Idarucizumab in Patients on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc02daa255cf2c78067efc13b0311ba8
https://pubmed.ncbi.nlm.nih.gov/26020620